Welcome to our dedicated page for Oncocyte Corporation SEC filings (Ticker: OCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a science-driven company like Oncocyte means wading through pages of clinical-trial updates, FDA-risk language and detailed R&D footnotes. If you have ever searched for Oncocyte insider trading Form 4 transactions or tried to parse dilution clauses buried in a 10-K, you know the challenge. Stock Titan solves this problem by turning every new disclosure into clear, actionable intelligence in seconds.
Our platform ingests each Oncocyte quarterly earnings report 10-Q filing, 8-K data drop and proxy statement the moment it hits EDGAR, then deploys AI to surface what matters: trial-milestone dates, cash-burn trends and leadership moves. With plain-language summaries, you’ll see Oncocyte annual report 10-K simplified, receive alerts on Oncocyte Form 4 insider transactions real-time, and get line-by-line commentary that makes understanding Oncocyte SEC documents with AI effortless. Whether you’re monitoring Oncocyte executive stock transactions Form 4, reviewing an Oncocyte earnings report filing analysis, or checking an Oncocyte 8-K material events explained note, the insights appear automatically—no scrolling through PDFs.
Professionals use these AI-powered summaries to compare segment revenue from liquid-biopsy assays, gauge the probability of FDA clearance, or verify details inside an Oncocyte proxy statement executive compensation section before voting. Real-time updates, comprehensive coverage of every form type, and concise expert context let you act sooner on critical developments—all while leaving the dense scientific jargon to us.
Insight Molecular Diagnostics Inc. (f/k/a Oncocyte) reported a noticeable uptick in commercial activity with net revenue of $518,000 for the quarter ended June 30, 2025 versus $104,000 a year earlier, and $2.656 million for the six months versus $280,000. Revenue growth was driven primarily by laboratory services and initial sales of the GraftAssureIQ kitted product.
Results show widening losses: a net loss of $9.742 million in the quarter (six-month loss of $16.413 million), as operating expenses rose to $10.192 million for the quarter, including a $2.804 million charge for the change in fair value of contingent consideration. Liquidity improved materially following a February 2025 registered offering that raised gross proceeds of approximately $29.1 million (net proceeds ~$28.7 million), leaving cash and cash equivalents of $24.3 million and combined cash plus restricted cash of $26.0 million at period end.
Operational and strategic developments include a corporate name and ticker change to IMDX and headquarters relocation to Nashville, an ongoing strategic partnership and investment with Bio-Rad, and a boosted Medicare reimbursement rate of $2,753 per result for GraftAssureCore. Significant noncurrent contingent consideration of $40.933 million and an accumulated deficit of $366.95 million remain on the balance sheet. Management concluded there is no substantial doubt about going concern for at least the next twelve months.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
